Publication: Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study
No Thumbnail Available
Identifiers
Date
2022-05-05
Authors
Cardoso, F.
Juric, D.
Lerebours, F.
Krop, I.
Borrego, M. Ruiz
Neven, P.
Park, Y. H.
Yardley, D.
Jhaveri, K.
Arce, C.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
